2022
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2022, 66: 23-32. PMID: 36255460, DOI: 10.1007/s00125-022-05815-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSGLT2 inhibitorsDrug categoriesSodium-glucose cotransporter 2 inhibitorsCardio-renal benefitsNormal blood glucose concentrationsCotransporter 2 inhibitorsClasses of medicationsAnti-inflammatory effectsSerious adverse effectsType 1 diabetesBlood glucose levelsBlood glucose concentrationKidney outcomesRare complicationBlood pressureSGLT2 inhibitionGlucose levelsKetone levelsBody weightType 2Ketone bodiesAdverse effectsGlucose concentrationInhibitorsEdged sword
2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018, 61: 2118-2125. PMID: 30132031, DOI: 10.1007/s00125-018-4663-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsWeight LossConceptsSGLT2 inhibitorsSodium-glucose cotransporter 2 inhibitorsPostprandial blood glucose levelsEuglycaemic diabetic ketoacidosisGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetic kidney diseaseGenitourinary tract infectionsLower extremity amputationHigh-risk individualsBlood glucose levelsPlasma glucose concentrationCardiovascular outcomesDiabetic ketoacidosisUrinary frequencyTract infectionsOptimal prescribingNew drug categoryKidney diseaseGlucose reabsorptionGlucose levelsHigh riskDrug categoriesBody weightBone fractures